← Back to Search

Cannabinoid

Low CBD session for Cannabis

Phase 2
Waitlist Available
Led By Brook L Henry, PhD
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up participants will be queried on a daily basis for six months using text messaging
Awards & highlights

Study Summary

This trial is looking at the acute effects of cannabis constituents on HIV-NP, long-term effects of cannabis use, and the impact of cannabis on endocannabinoid function in people living with HIV-NP.

Eligible Conditions
  • Cannabis
  • Neuropathy
  • Complex Regional Pain Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~participants will be queried on a daily basis for six months using text messaging
This trial's timeline: 3 weeks for screening, Varies for treatment, and participants will be queried on a daily basis for six months using text messaging for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pain
Pain
Secondary outcome measures
Phase 1 - Marijuana subscale (M-scale) of the Addiction Research Center Inventory (ARCI)
Phase 1 - Neuropsychological Assessment Battery
Phase 1 - Patient Global Impression of Change (PGIC)
+3 more

Trial Design

3Treatment groups
Active Control
Group I: Low CBD sessionActive Control1 Intervention
In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.6% THC + 0.09 CBD. They will then undergo experimental testing as described below under Outcome Measures.
Group II: Medium CBD sessionActive Control1 Intervention
In the morning, participants will inhale 8 puffs of vaporized cannabis 4 puffs will contain 1.6% THC + 0.09 CBD and 4 puffs will contain 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.
Group III: High CBD sessionActive Control1 Intervention
In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.

Find a Location

Who is running the clinical trial?

University of California, San DiegoLead Sponsor
1,130 Previous Clinical Trials
1,552,812 Total Patients Enrolled
4 Trials studying Cannabis
343 Patients Enrolled for Cannabis
Brook L Henry, PhDPrincipal InvestigatorUniversity of California, San Diego
~6 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top